Zoekresultaten - 6 results
Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer
cancer screening data and the national cancer registry, demonstrates excellent protection against invasive cervical cancer among girls immunized at the age of 12 to 13 years with the bivalent human ...
Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
to international criteria is prerequisite for their implementation in cervical cancer screening. OncoPredict HPV Quantitative Typing (QT) assay (Hiantis Srl, Milan, Italy) is a novel full-genotyping ...
Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance
Publication Type: Peer reviewed scientific article Authors: Prétet, Jean Luc; Arroyo Mühr, Laila Sara; Cuschieri, Kate; Fellner, María Dolores; Correa, Rita Mariel; Picconi, María Alejandra; Garland, Suzanne M.; Murray, Gerald L.; Molano, Monica; Michael ...
Can REALQUALITY RQ-HPV screen be considered as a clinically validated HPV test for use in cervical cancer screening?
Detection of Cancer Female Humans Mass Screening Papillomaviridae Papillomavirus Infections Uterine Cervical Dysplasia Uterine Cervical Neoplasms Vaginal Smears Abstract: “Can REALQUALITY RQ- HPV screen be ...
HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions.
Uterine Cervical Neoplasms Abstract: In 2017, cervical cancer screening in the Netherlands switched from cytology to human papillomavirus (HPV) testing using the validated PCR-based cobas 4800. Women could ...
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework
Kate; M. Arbyn Source: Journal of Medical Virology, Volume 95, Issue 1 (2023) Keywords: cervical cancer HPV genotyping human papillomavirus OncoPredict HPV® test validation. VALGENT Abstract: Human ...